Table 2.
Relationship between miR-519d level and clinicopathologic features (N = 60)
| Characteristics | No. of Patients | miR-519d Δ Cta | Non-parametric | P value | |
|---|---|---|---|---|---|
| No. | % | Mean ± SD | test value | ||
| Age (years) | |||||
| < 60 | 36 | 60.0 | 8.93 ± 2.94 | Z = -0.362 | 0.717 |
| ≥ 60 | 24 | 40.0 | 9.13 ± 3.01 | ||
| Gender | |||||
| Female | 19 | 31.7 | 8.91 ± 3.35 | Z = -0.358 | 0.721 |
| Male | 41 | 68.3 | 9.06 ± 2.78 | ||
| Smoking history | |||||
| Nonsmoker | 32 | 53.3 | 8.93 ± 3.35 | Z = -0.756 | 0.450 |
| Smoker | 28 | 46.7 | 9.10 ± 2.45 | ||
| Alcohol history | |||||
| Nondrinker | 38 | 63.3 | 8.97 ± 3.19 | Z = -0.337 | 0.736 |
| Drinker | 22 | 36.7 | 9.08 ± 2.54 | ||
| Tumor size (cm) | |||||
| ≤ 4 | 32 | 53.3 | 8.67 ± 3.24 | Z = -1.719 | 0.086 |
| > 4 | 28 | 46.7 | 9.40 ± 2.56 | ||
| Lymph node metastasis | |||||
| pN0 | 28 | 46.7 | 8.19 ± 2.47 | Z = -3.123 | 0.037 |
| pN1 to pN2 | 32 | 53.3 | 9.73 ± 3.17 | ||
| TNM stage | |||||
| I-II | 22 | 36.7 | 7.60 ± 2.24 | Z = -3.206 | 0.001 |
| III-IV | 38 | 63.3 | 9.83 ± 3.02 | ||
| Pathological differentiation | |||||
| Well | 25 | 41.7 | 8.64 ± 2.72 | Z = -0.787 | 0.431 |
| Moderately/poorly | 35 | 58.3 | 9.28 ± 3.10 | ||
| Disease Site | |||||
| Tongue | 25 | 41.7 | 8.44 ± 2.69 | H = 5.242 | 0.263 |
| Gingival | 8 | 13.3 | 11.09 ± 3.59 | ||
| Cheek | 9 | 15.0 | 9.82 ± 3.21 | ||
| Floor of Mouth | 12 | 20.0 | 8.50 ± 2.52 | ||
| Oropharynx | 6 | 10.0 | 8.41 ± 2.85 | ||
| Recurrence | |||||
| No | 50 | 22.5 | 9.02 ± 3.18 | Z = -0.635 | 0.526 |
| Yes | 10 | 77.5 | 8.96 ± 1.36 | ||
Abbreviations: SD, standard deviation; pN, pathological lymph node status; TNM stage, tumor-lymph node-metastasis stage.
aΔ Ct indicates the difference in the cycle number at which a sample's fluorescent signal passes a given threshold above baseline (Ct) derived from a specific gene compared with that of β-actin in tumor tissues.